Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. develops and sells ophthalmic medical technology for customized vision after cataract surgery. Its RxSight Light Adjustable Lens system includes Light Adjustable Lens products, the Light Delivery Device and related accessories, enabling post-operative adjustment of an intraocular lens based on patient visual feedback.
RxSight news commonly covers financial results, sales guidance, Light Adjustable Lens unit demand, Light Delivery Device placements and installed-base growth. Company updates also address clinical evidence presented in cataract and refractive surgery forums, regulatory approvals in international markets, healthcare conference participation and executive finance leadership changes.
RxSight, Inc., an ophthalmic medical device company, announced the addition of three new members to its Board of Directors effective August 3, 2021, following its IPO. New board members include Robert Palmisano, Robert Warner, and Julie Andrews, who bring extensive experience in commercial operations and finance. Concurrently, four longstanding board members resigned. RxSight aims to enhance patient vision post-cataract surgery with its innovative Light Adjustable Lens technology. The company expresses optimism regarding its future growth and transformation in the cataract surgery market.
RxSight, Inc. has completed its initial public offering (IPO) of 7,350,000 shares of common stock at $16.00 per share, generating approximately $132 million in gross proceeds. The offering includes the underwriters’ option to purchase an additional 898,594 shares, bringing the total to 8,248,594 shares sold. The shares started trading on Nasdaq under the symbol RXST on July 30, 2021. RxSight specializes in ophthalmic medical devices, particularly the innovative Light Adjustable Lens system designed to enhance patients' vision post-cataract surgery.
RxSight, an ophthalmic medical device company, has priced its initial public offering at $16.00 per share, raising approximately $117.6 million from the sale of 7,350,000 shares. The offering is set to close on August 3, 2021, pending customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to 1,102,500 shares. Trading on the Nasdaq will commence on July 30, 2021, under the ticker symbol RXST. This IPO marks a significant step for RxSight, as it aims to enhance the experience of patients post-cataract surgery.